"We will exhibit at the Pharma Lab EXPO Tokyo" - New solution for subcutaneous injection drug release testing - BioJECT Cell
We are pleased to announce that SOTAX, in close collaboration with the National University of Singapore, has developed a new BioJECT cell (patent pending) compatible with the CE7smart (SOTAX JP3 (USP4) flow-through cell dissolution testing device) as a new solution for in vitro testing of subcutaneous injection drugs such as insulin. This cell features a small container called a biomatrix for filling samples, allowing for testing that simulates subcutaneous tissue. By combining the BioJECT cell with the CE7smart, we support the development of effective testing methods for various subcutaneous injection drugs, including in-situ implants, peptides, and low molecular weight compounds. ■ Exhibition Name: 7th Pharma Lab EXPO Tokyo ■ Dates: July 9 (Wed) - 11 (Fri), 2025 ■ Time: 10:00 AM - 5:00 PM ■ Venue: Tokyo Big Sight ■ Booth Number: E6-26
Inquire About This Product
basic information
- Compliant with JP3 (USP4) standards - Supports 6 samples - Hydrodynamic properties have been demonstrated - Evaluation possible without using membranes that are difficult to characterize and are susceptible to batch variation - Easy adjustment of the gel used, allowing for increased selectivity of release with compound addition
Price information
Please contact us.
Delivery Time
※Please contact us.
Applications/Examples of results
Pharmaceutical and chemical industry
catalog(2)
Download All CatalogsNews about this product(2)
Company information
DKSH is a member of the Swiss global company "DKSH Group." It provides comprehensive services and solutions across the entire value chain, combining procurement, marketing, sales, distribution, and after-sales service, through its three business divisions: consumer goods, production materials, and technology, with a long-term perspective.